Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that a clinical study conducted by its wholly-owned subsidiary, KGK Science Inc, has shown positive results of its GJ 191 supplementation (JointAlive) in treating osteoarthritis.
The randomized, double-blind, placebo-controlled intervention demonstrated that supplementation with GJ 191 provided reductions in current knee pain at six and 12 weeks. Additionally, after 12 weeks, 53% of participants reported a clinically important improvement in knee symptoms. Seventy-two males and females between 40-73 years were enrolled in the study and participants consumed either GJ 191 or a placebo daily for 12 weeks.
“This clinically meaningful change has impact on this population of patients with self-reported knee pain,” Dr Mal Evans, chief scientific officer at KGK Science said in a statement.
READ: Wellbeing Digital Sciences says KGK Science subsidiary hails FDA’s commitment to release NDI draft guidance documents in near future
Chenland Nutritionals’ CTO, Dr Zimin Liu, added, “JointAlive is the first TCM-based formulation which promotes joint health in as quickly as 7 days, improves joint flexibility and helps maintain healthy joints. In addition, it has been notified to the Food and Drug Administration, without objection, as a New Dietary Ingredient and on 3 structure-function claims. This study is a critical step in providing consumers with scientifically based and safe alternatives for addressing aches and discomfort and bringing natural health products to market.”
GJ 191 is a natural health product developed by Chenland Nutritionals Inc and is a formulation of three Traditional Chinese Medicinal ingredients including Epimedium, Salvia miltiorrhiza, and Dioscorea extracts.
In the recent study conducted by KGK investigating GJ 191 supplementation, results showed it to be safe and efficacious in improving knee joint function in adults with knee osteoarthritis and self-reported knee pain in people who were otherwise healthy.
Wellbeing Digital Science iss an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research
Contact the author at jon.hopkins@proactiveinvestors.com
